Ratings by Wolfe Research (Rudy Li)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/22/2026 | Alto Neuroscience | ANRO | New Coverage | Outperform (N/A) |
21.54 (24.44) |
13.46% | Details | |
| 5/22/2026 | Compass Pathways | CMPS | New Coverage | Outperform (N/A) |
11.59 (12.65) |
9.15% | Details | |
| 5/22/2026 | Immunic Inc. | IMUX | New Coverage | Outperform (N/A) |
12.30 (15.07) |
22.52% | Details | |
| 3/31/2026 | Centessa Pharmaceuticals | CNTA | Downgrade | Peerperform (Outperform) |
27.58 (40.50) |
46.85% | Details | |
| 2/24/2026 | uniQure BV | QURE | New Coverage | Peerperform (N/A) |
23.43 (49.04) |
109.3% | Details | |
| 2/24/2026 | Stoke Therapeutics | STOK | New Coverage | Outperform (N/A) |
34.29 (31.11) |
-9.27% | Details | |
| 2/24/2026 | Xenon Pharmaceuticals | XENE | New Coverage | Outperform (N/A) |
42.23 (54.61) |
29.32% | Details | |
| 2/24/2026 | Axsome Therapeutics | AXSM | New Coverage | Outperform (N/A) |
183.72 (241.97) |
31.71% | Details | |
| 2/24/2026 | Neurocrine Bio. | NBIX | New Coverage | Outperform (N/A) |
128.63 (161.44) |
25.51% | Details | |
| 2/24/2026 | Praxis Precision Medicines Inc. | PRAX | New Coverage | Outperform (N/A) |
335.28 (305.37) |
-8.92% | Details | |
| 2/24/2026 | Acadia Pharmaceuticals | ACAD | New Coverage | Outperform (N/A) |
23.99 (22.60) |
-5.79% | Details | |
| 2/24/2026 | Denali Therapeutics Inc. | DNLI | New Coverage | Peerperform (N/A) |
20.19 (24.77) |
22.68% | Details | |
| 2/24/2026 | Alkermes | ALKS | New Coverage | Outperform (N/A) |
31.91 (48.07) |
50.64% | Details | |
| 2/24/2026 | Centessa Pharmaceuticals | CNTA | New Coverage | Outperform (N/A) |
24.50 (27.58) |
12.57% | Details | |
| 2/23/2026 | Definium Therapeutics Inc | DFTX | New Coverage | Outperform (N/A) |
17.13 (36.18) |
111.21% | Details |
